Background:
Worldwide, lung cancer is the major cause of deaths due to cancer.
Most of the lung cancer cases are categorized as 85% cases of non-small cell lung
cancer, while remainder 15% cases are known as small cell lung cancer. The long survival
time as well as the improved quality of life for patients undergoing lung cancer using
conventional chemotherapy is still not satisfactory. Therefore, robust research undergoes
development of drug delivery system which increased drug at target side with reduced
systemic side effect.
Method:
Bibliography database reviewed various inhalable nanostructured drug delivery
strategies for effective delivery of anticancer drugs to lung cancer which are designed to
improve the therapeutic index of anticancer drugs throughout improvement of their stability
as well as bioavailability.
Results:
It has been reported that nanostructure based inhalation chemotherapy is more
successful targeting system and also offers reduced side effects than conventional chemotherapy.
Conclusion:
Thus, the review highlights the critical issues, strategies for delivery and
provides detail on various inhalable nanostructures for anticancer drug delivery along
with toxicity concerns as well as rationale behind development of inhalable nanostructures.
A Combined Epigenetic Therapy Equals the Efficacy of Conventional Chemotherapy in Refractory Advanced Non–Small Cell Lung Cancer: Figure 1.
